JP Morgan Chase
DNLI icon

JP Morgan Chase’s Denali Therapeutics DNLI Stock Holding History

JP Morgan Chase’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30,000
Closed -$408K – 7205
2025
Q1 		$408K Buy
+30,000
New +$575K ﹤0.01% 4892
2024
Q3 		– Sell
-30,000
Closed -$697K – 7462
2024
Q2 		$697K Buy
+30,000
New +$576K ﹤0.01% 4499

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase's DNLI Position: Q1 2026 in Review

JP Morgan Chase increased its Denali Therapeutics (DNLI) stake by 88% in Q1 2026, buying an estimated $3.03M and bringing the position to 323,989 shares worth $5.86M. The position accounts for ﹤0.01% of the portfolio, ranked #3170.

JP Morgan Chase first reported a position in DNLI in Q1 2018 and has held it in 33 quarters since. The position peaked at $27.7M in Q4 2020. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • JP Morgan Chase held 323,989 shares of Denali Therapeutics worth $5.86M as of Q1 2026.
  • JP Morgan Chase bought 152,041 Denali Therapeutics shares in Q1 2026, an estimated $3.03M.
  • Denali Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3170 holding.
  • JP Morgan Chase first reported a position in Denali Therapeutics in Q1 2018 and has held it in 33 quarters since.
  • JP Morgan Chase's Denali Therapeutics position peaked at $27.7M in Q4 2020.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.